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OBJECTIVE— To study the association of the inflammatory markers serum amyloid A (SAA)
and C-reactive protein (CRP) with retinal microvascular parameters in hypertensive individuals
with and without type 2 diabetes.
RESEARCHDESIGNANDMETHODS— This cross-sectional analysis was a substudy
in 711 patients (159 with and 552 without diabetes) of the Anglo-Scandinavian Cardiac Out-
comes Trial (ASCOT) based on digital 30-degree images of superior and inferior temporal retinal
fields.
RESULTS— SAA was associated with arteriolar length-to-diameter ratio positively in nondi-
abetic patients (Ptrend  0.028) but negatively in diabetic patients (Ptrend  0.005). The differ-
ence was unlikely to be a chance finding (P 0.007 for interaction). Similar results were found
for the association of SAA with arteriolar tortuosity (P 0.05 for interaction). Associations were
less pronounced for CRP and retinal parameters.
CONCLUSIONS— Inflammatory processes are differentially involved in retinal microvas-
cular disease in diabetic compared with nondiabetic hypertensive individuals.
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R etinal microvascular changes havebeen associated with inflammatoryprocesses, which in turn have been
shown to be involved in the pathogenesis
of vascular disease (1–3). Serum amyloid
A (SAA) is a sensitive indicator of inflam-
mation with an expanded range and ki-
netics different from those associated with
C-reactive protein (CRP) (4). Although
levels of SAA and CRP have been shown
to be associated with retinal vessel di-
mensions (2), it is currently unknown
whether this association differs between
individuals with and without diabetes.
RESEARCH DESIGN AND
METHODS— This cross-sectional
analysis was a prespecified substudy at
two centers (London, U.K., and Dublin,
Ireland) of the Anglo-Scandinavian Car-
diac Outcomes Trial (ASCOT), a random-
ized controlled multicenter trial assessing
the effect of two antihypertensive regi-
mens on coronary heart disease end
points (5– 8). Ethics approval was ob-
tained at both study sites, and all partici-
pants gave written informed consent. In
addition to hypertension, individuals had
at least three of the following risk factors:
male sex, age 55 years, micro- or mac-
roproteinuria, smoking history, dyslipi-
demia, family history of premature CHD,
electrocardiogram abnormalities, left
ventricular hypertrophy, type 2 diabetes,
peripheral arterial disease, and previous
stroke or transient ischemic attack. Reti-
nal analyses were performed on digital
30-degree images of superior and inferior
temporal fields as previously described
(9). Arteriolar vessels were assessed up to
third-generation branches as prespecified
in the protocol. SAA and CRP concentra-
tions were measured on a Dade Behring
Nephelometer II (Dade Behring Diagnos-
tic, Marburg, Germany). Coefficients of
variation for intra- and interassay preci-
sion were 5.2 and 8.5%, respectively
(10). Clinical and biochemical parame-
ters of diabetic and nondiabetic patients
were compared using Student’s t test; pa-
rameters were transformed if nonnor-
mally distributed. Values are given
as means  SD if normally distributed
and, otherwise, as median (interquartile
range). Multiple linear regression analysis
was used to compare retinal parameters
between diabetic and nondiabetic indi-
viduals and to investigate the associations
between SAA or CRP and retinal parame-
ters. Prespecified explanatory variables
for all models were age, sex, BMI, smok-
ing status, and randomization to antihy-
pertensive and lipid-lowering treatment
in ASCOT. SAA and CRP were catego-
rized by tertiles and analyzed as categori-
cal and ordered factors (2). Statistical
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analyses were performed using Stata 10.0
(Stata Corporation, College Station, TX).
RESULTS— This study included 711
individuals (159 with and 552 without
diabetes). Age was similar in diabetic and
nondiabetic patients (61.4  8.5 vs.
61.5 7.7 years, respectively; P 0.86),
and the proportion of female participants
was comparable (25.8 vs. 21.2%; P 
0.22). Diabetic patients had higher BMI
(30.6  5.4 vs. 28.8  4.3 kg/m2; P 
0.001). Systolic blood pressure in dia-
betic and nondiabetic individuals was
159.1  19.1 vs. 159.5  16.9 mmHg,
respectively, (P  0.78); diastolic blood
pressure was 90.4  9.9 vs. 93.8  9.7
mmHg (P  0.001). Levels of CRP were
similar in diabetic and nondiabetic indi-
viduals (median 1.69 mg/l [interquartile
range 0.86–3.55] vs. 1.52 [0.77–3.39];
P  0.44), but SAA was significantly
higher in diabetic than in nondiabetic in-
dividuals (3.15 mg/l [2.05–4.90] vs. 2.65
[1.60–4.60]; P 0.03). Diabetic individ-
uals had shorter retinal arteriolar vessels
than nondiabetic individuals (446.9 
103.7 vs. 466.4 126.8 pixels; P 0.03)
with larger diameters (29.3  3.1 vs.
28.3  3.2 pixels; P  0.001). This re-
sulted in a significantly lower arteriolar
length-to-diameter (L:D) ratio in diabetic
individuals (12.8 [9.9 –15.5] vs. 13.8
[11.2–17.0]; P 0.001). Arteriolar tortu-
osity tended to be lower in diabetic than
in nondiabetic individuals, but differ-
ences were not statistically significant
(1.25  102 [0.63–2.27] vs. 1.48 
102 [0.74–2.80]; P  0.31). Figure 1A
shows the association of SAA with arterio-
lar L:D ratio in diabetic and nondiabetic
individuals. In diabetic patients, the asso-
ciation between SAA and arteriolar L:D
ratio was negative (Ptrend  0.005),
whereas in nondiabetic patients, levels of
SAA were positively associated with arte-
riolar L:D ratio (Ptrend  0.028). The
differences between diabetic and nondia-
betic patients were confirmed in an inter-
action test (P 0.007). The association of
SAA and arteriolar tortuosity showed sim-
ilar findings (Fig. 1B; P  0.05 for inter-
action by diabetes status). No consistent
association was found for CRP and arte-
riolar L:D ratio (Fig. 1C), and there was a
positive association between CRP and ar-
teriolar tortuosity only for nondiabetic
patients (Ptrend  0.039). There were no
significant associations between venular
parameters and either SAA or CRP.
CONCLUSIONS— Diabetes status
has a modifying effect on the association
of SAA with retinal arteriolar architecture.
Whereas increased levels of SAA were as-
sociated with higher L:D ratio and tortu-
osity in nondiabetic patients, inverse
findings were observed in diabetic pa-
tients. Interaction tests confirmed that the
modifying effect of diabetes status was
unlikely to be a chance finding. CRP mea-
surements showed less consistent associ-
Figure 1—Association of SAA and CRP (categorized in tertiles) with arteriolar L:D ratio (A andC) and with arteriolar tortuosity (B andD). Ranges
for tertiles 1, 2, and 3 (t1, t2, and t3, respectively) for SAA were 0.6–2.4, 2.5–3.9, and 4.0–92.6 mg/l, respectively, for diabetic individuals and
0.6–2.0, 2.1–3.6, and 3.7–162.0 mg/l for nondiabetic individuals. The corresponding values for CRP were 0.1–1.0, 1.0–2.7, and 2.8–49.8 mg/l for
diabetic individuals and 0.1–1.0, 1.0–2.4, and 2.4–65.2 mg/l for nondiabetic individuals. P values for trend are derived from multiple linear
regression analysis models adjusted for age, sex, BMI, smoking status, and antihypertensive and lipid-lowering treatment in the ASCOT and represent
the association between inflammatory markers and retinal parameters over the entire range of SAA or CRP. *P  0.05 for comparison with t1.
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ations with arteriolar measures according
to diabetes status.
Previous studies have consistently
shown an association of inflammatory
markers with retinal microvascular
changes but have not reported results ac-
cording to diabetes status (1–3). In the
Beaver Dam Eye Study, increased levels of
SAA were associated with smaller arterio-
lar diameters (2). Because a smaller arte-
riolar diameter results in an increased L:D
ratio, these findings are compatible with
those for nondiabetic individuals in the
present analysis. It is noteworthy that
participants in the Beaver Dam Eye
Study mainly consisted of nondiabetic
individuals (7.1% with diabetes) and
exhibited a lower frequency of cardio-
vascular risk factors than participants in
the ASCOT (2).
CRP and SAA are classic acute-phase
proteins, and their levels are often corre-
lated (11). However, their concentration
may differ due to diverse regulation by the
cytokine network and differences in
clearance rates (12). It is, therefore, not
surprising that these two markers may
differ in individuals with multiple and
different underlying pathologies, such as
hypertensive patients with and without
type 2 diabetes. In particular, recent stud-
ies have suggested that SAA may be a
more sensitive indicator of inflammation
in cardiovascular and noncardiovascular
disease than CRP (13–15), although other
studies have not confirmed this (12).
The cross-sectional design of this
study limits conclusions regarding
cause and effect. Although analyses
were adjusted for relevant cardiovascu-
lar risk factors, this does not exclude the
possibility that the analyses did not ac-
count for all potential confounders. In
conclusion, the present findings suggest
the involvement of diverse inflamma-
tory mechanisms for the development
of retinal microvascular disease in dia-
betic individuals compared with that for
nondiabetic individuals—a concept
that may need further investigation.
Acknowledgments— This study was sup-
ported by the Swiss National Science Founda-
tion (grant 3233B0-115212 to C.S.). N.C.,
A.D.H., N.P., and S.T. are grateful for support
from the National Institute for Health Re-
search, Biomedical Research Centre funding
scheme. R.J.T. is supported by a Sidney Sax
fellowship from the National Health and Med-
ical Research Council of Australia (grant
334173).
This study was supported by an unre-
stricted grant from Pfizer. No other potential
conflicts of interest relevant to this article were
reported.
We thank the staff and participants of the
ASCOT for their important contribution to
the study. We are grateful to M. Pepys from the
Centre for Amyloidosis and Acute Phase Pro-
teins, Royal Free and University College Med-
ical School, London, U.K., for important
support regarding the biochemical analyses.
References
1. Ikram MK, de Jong FJ, Vingerling JR, Wit-
teman JC, Hofman A, Breteler MM, de
Jong PT. Are retinal arteriolar or venular
diameters associated with markers for car-
diovascular disorders? The Rotterdam
Study. Invest Ophthalmol Vis Sci 2004;
45:2129–2134
2. Klein R, Klein BE, Knudtson MD, Wong
TY, Tsai MY. Are inflammatory factors re-
lated to retinal vessel caliber? The Beaver
Dam Eye Study. Arch Ophthalmol 2006;
124:87–94
3. Ross R. Atherosclerosis–an inflammatory
disease. N Engl J Med 1999;340:115–126
4. Malle E, De Beer FC. Human serum amy-
loid A (SAA) protein: a prominent acute-
phase reactant for clinical practice. Eur
J Clin Invest 1996;26:427–435
5. Sever PS, Dahlof B, Poulter NR, Wedel H,
Beevers G, Caulfield M, Collins R, Kjeld-
sen SE, McInnes GT, Mehlsen J, Niemi-
nen M, O’Brien E, Ostergren J. Rationale,
design, methods and baseline demogra-
phy of participants of the Anglo-Scandi-
navian Cardiac Outcomes Trial: ASCOT
investigators. J Hypertens 2001;19:1139–
1147
6. Stanton A, Fitzgerald D, Hughes A, Mayet
J, O’Brien E, Poulter N, Sever P, Shields D,
Thom S. An intensive phenotyping study
to enable the future examination of ge-
netic influences on hypertension-associ-
ated cardiovascular disease. J Hum
Hypertens 2001;15(Suppl. 1):S13–S18
7. Sever PS, Dahlof B, Poulter NR, Wedel H,
Beevers G, Caulfield M, Collins R, Kjeld-
sen SE, Kristinsson A, McInnes GT,
Mehlsen J, Nieminen M, O’Brien E, Oster-
gren J. Prevention of coronary and stroke
events with atorvastatin in hypertensive
patients who have average or lower-than-
average cholesterol concentrations, in the
Anglo-Scandinavian Cardiac Outcomes
Trial–Lipid Lowering Arm (ASCOT-
LLA): a multicentre randomised con-
trolled trial. Lancet 2003;361:1149–
1158
8. Dahlof B, Sever PS, Poulter NR, Wedel H,
Beevers DG, Caulfield M, Collins R, Kjeld-
sen SE, Kristinsson A, McInnes GT,
Mehlsen J, Nieminen M, O’Brien E, Oster-
gren J. Prevention of cardiovascular
events with an antihypertensive regi-
men of amlodipine adding perindopril
as required versus atenolol adding ben-
droflumethiazide as required, in the An-
glo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm
(ASCOT-BPLA): a multicentre random-
ised controlled trial. Lancet 2005;366:
895–906
9. Witt N, Wong TY, Hughes AD, Chatur-
vedi N, Klein BE, Evans R, McNamara M,
Thom SA, Klein R. Abnormalities of reti-
nal microvascular structure and risk of
mortality from ischemic heart disease and
stroke. Hypertension 2006;47:975–981
10. Ledue TB, Weiner DL, Sipe JD, Poulin SE,
Collins MF, Rifai N. Analytical evaluation
of particle-enhanced immunonephelo-
metric assays for C-reactive protein, se-
rum amyloid A and mannose-binding
protein in human serum. Ann Clin Bio-
chem 1998;35:745–753
11. McAdam KP, Elin RJ, Sipe JD, Wolff SM.
Changes in human serum amyloid A and
C-reactive protein after etiocholanolone-
induced inflammation. J Clin Invest 1978;
61:390–394
12. Raynes JG, Cooper EH. Comparison of se-
rum amyloid A protein and C-reactive
protein concentrations in cancer and non-
malignant disease. J Clin Pathol 1983;36:
798–803
13. Katayama T, Nakashima H, Takagi C,
Honda Y, Suzuki S, Iwasaki Y, Yamamoto
T, Yoshioka M, Yano K. Serum amyloid a
protein as a predictor of cardiac rupture in
acute myocardial infarction patients fol-
lowing primary coronary angioplasty.
Circ J 2006;70:530–535
14. Katayama T, Nakashima H, Takagi C,
Honda Y, Suzuki S, Iwasaki Y, Yano K.
Prognostic value of serum amyloid A pro-
tein in patients with acute myocardial in-
farction. Circ J 2005;69:1186–1191
15. Kokubun M, Imafuku Y, Okada M, Ohgu-
chi Y, Ashikawa T, Yamada T, Yoshida H.
Serum amyloid A (SAA) concentration
varies among rheumatoid arthritis pa-
tients estimated by SAA/CRP ratio. Clin
Chim Acta 2005;360:97–102
Inflammatory markers and retinal vascular change
1100 DIABETES CARE, VOLUME 32, NUMBER 6, JUNE 2009
